展望2024:提振信心,推动中国生物医药产业高质量平衡发展
Outlook 2024:Boosting Confidence and Promoting the High-quality and Balanced Development of China's Biopharmaceutical Industry
戈乾玮 1孔令辉 1邵黎明2
作者信息
- 1. 复旦大学药学院,上海 201203
- 2. 复旦大学药学院,上海 201203;上海市药物研发协同创新中心,上海 201203
- 折叠
摘要
2023年,中国生物医药行业进入自主创新引领的关键转变时期.2024年,生物医药产业将持续优化行业生态,平衡各方需求,注重差异化发展.上海市药物研发协同创新中心通过多轮头脑风暴圆桌会议,对我国生物医药行业进行了2024年度展望,提出生物医药行业需要提振信心,在困难中抓住机遇,追求高质量平衡发展.
Abstract
In 2023,China's biopharmaceutical industry has undergone a significant transformation driven by independent innovation.In 2024,the biopharmaceutical industry will continue to optimize the industry ecosystem,harmonize diverse needs,and focus on differentiated development.Through multiple rounds of brainstorming roundtables,Shanghai Center for Innovation Drug Discovery and Development(SCIDDD)made the 2024 annual outlook on China's biopharmaceutical industry,proposing that the biopharmaceutical industry needs to boost confidence,seize opportunities amid difficulties,and pursue high-quality and balanced development.
关键词
医药行业/高质量平衡发展/创新药Key words
pharmaceutical industry/high-quality and balanced development/innovative drug引用本文复制引用
出版年
2024
NETL
NSTL
维普
万方数据